We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Aripiprazole in Patients With a History of Bipolar Disorder

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00036348
First Posted: May 10, 2002
Last Update Posted: November 11, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
  Purpose
The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with a history of bipolar disorder.

Condition Intervention Phase
Bipolar Disorder Drug: Aripiprazole Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Study Start Date: March 2000
Study Completion Date: June 2003
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Patients with a history of Bipolar I Disorder
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00036348


Locations
United States, Alabama
Local Institution
Birmingham, Alabama, United States
Local Institution
Tuscaloosa, Alabama, United States
United States, California
Local Institution
Chillicothe, California, United States
Local Institution
Riverside, California, United States
Local Institution
Stanford, California, United States
Local Institution
Torrance, California, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Louisiana
Local Institution
Shreveport, Louisiana, United States
United States, Massachusetts
Local Institution
Belmont, Massachusetts, United States
United States, Nevada
Local Institution
Las Vegas, Nevada, United States
United States, New Mexico
Local Institution
Albuquerque, New Mexico, United States
United States, New York
Local Institution
New York, New York, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
United States, Tennessee
Local Institution
Memphis, Tennessee, United States
Local Institution
Nashville, Tennessee, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
San Antonio, Texas, United States
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00036348     History of Changes
Other Study ID Numbers: CN138-010
First Submitted: May 8, 2002
First Posted: May 10, 2002
Last Update Posted: November 11, 2013
Last Verified: September 2007

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Bipolar I disorder

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Aripiprazole
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs


To Top